Alzheimer’s: Type 3 diabetes
Have you heard that Alzheimer’s disease (AD) is now being called Type 3 diabetes? This article is one of many stating:
growing evidence supports the concept that AD is fundamentally a metabolic disease with substantial and progressive derangements in brain glucose utilization and responsiveness to insulin and insulin-like growth factor [IGF] stimulation.
And because the disease has many aspects to it including:
impairments in energy metabolism, increased oxidative stress, inflammation, insulin and IGF resistance, and insulin/IGF deficiency in the brain…
…it is imperative that future therapeutic strategies for AD abandon the concept of uni-modal therapy in favor of multi-modal treatments that target distinct impairments at different levels within the brain insulin/IGF signaling cascades.
The article also has a simplified diagram of the process under which it states:
High caloric intake and/or chronic low-level nitrosamine exposures [through diet, smoking, agriculture], promote fatty liver disease (steatohepatitis) that progresses due to injury and inflammation, eventually leading to hepatic insulin resistance. The same poor physiological states also promote obesity, diabetes mellitus, and other peripheral insulin resistance diseases. Toxic lipids, including ceramides, made in the liver, get released into the circulation, cross the blood-brain barrier, and cause brain insulin resistance, inflammation, energy failure, toxicity, and local production of toxic ceramides. The end result is progressive neurodegeneration, including Alzheimer’s disease.
How much you wanna bet ALS is Type 4 diabetes?
Read Full Post | Make a Comment ( 1 so far )
A Path to Health 